# Immunogenicity and Safety of Verorab™ in Indian Population

> **NCT00260351** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 405 (actual)

## Conditions studied

- Rabies

## Interventions

- **BIOLOGICAL:** Purified Verocell Rabies Vaccine
- **BIOLOGICAL:** Purified Verocell Rabies Vaccine
- **BIOLOGICAL:** Purified Verocell Rabies Vaccine

## Key facts

- **NCT ID:** NCT00260351
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2008-08
- **Final completion:** 2008-10
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00260351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00260351, "Immunogenicity and Safety of Verorab™ in Indian Population". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00260351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*